Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer
about
Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangiomaEGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy.Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer
P2860
Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 May 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer
@en
Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer.
@nl
type
label
Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer
@en
Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer.
@nl
prefLabel
Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer
@en
Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer.
@nl
P2093
P2860
P50
P1476
Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer
@en
P2093
Allison W Lorenzen
George W Woodfield
James P De Andrade
Jennifer C Carr
Philip M Spanheimer
P2860
P2888
P304
P356
10.1245/S10434-015-4597-X
P577
2015-05-14T00:00:00Z
P6179
1021816695